Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
Solitary plasmacytoma (SP) is characterized by a localized mass of clonal plasma cells with
no or minimal bone marrow plasmacytosis. It can present either as EMP or SBP. Radiotherapy is
the first-line treatment with high response rate. However, 65-84% SBP patients and 25-35% EMP
patients progress at 10 years. We aimed to investigate whether adjuvant bortezomib based
chemotherapy with radiotherapy could prolong event-free survival in treatment-naive SP
patients compared to that with radiotherapy alone.